Dabrafenib and Trametinib for the Treatment of Pediatric and Adolescent Melanoma: Single Center Experience Data From Italian Compassionate Use
Stefano Chiaravalli(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrea Ferrari(University of Milan), Michela Casanova(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Maura Massimino(Fondazione IRCCS Istituto Nazionale dei Tumori), Luca Bergamaschi(Fondazione IRCCS Istituto Nazionale dei Tumori), Alice Indini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 6
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978